Screening for osteogenic activity in extracts from Irish marine organisms: The potential of Ceramium pallidum by Carson, Matthew A et al.
Screening for osteogenic activity in extracts from Irish marine
organisms: The potential of Ceramium pallidum
Carson, M. A., Nelson, J., Cancela, M. L., Laizé, V., Gavaia, P. J., Rae, M., ... Clarke, S. A. (2018). Screening for
osteogenic activity in extracts from Irish marine organisms: The potential of Ceramium pallidum. PLoS ONE,
13(11), e0207303. https://doi.org/10.1371/journal.pone.0207303
Published in:
PLoS ONE
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2018 the authors.
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:05. Apr. 2019
RESEARCH ARTICLE
Screening for osteogenic activity in extracts
from Irish marine organisms: The potential of
Ceramium pallidum
Matthew A. CarsonID1, John Nelson2, M. Leonor Cancela3,4,5, Vincent Laize´3, Paulo
J. Gavaia3, Margaret Rae6, Svenja Heesch7, Eugene Verzin8, Brendan F. GilmoreID9, Susan
A. Clarke1*
1 School of Nursing and Midwifery, Queen’s University Belfast, Belfast, United Kingdom, 2 School of
Biological Sciences, Queen’s University Belfast, Belfast, United Kingdom, 3 Centre of Marine Sciences
(CCMAR), University of Algarve, Faro, Portugal, 4 Department of Biomedical Sciences and Medicine,
University of Algarve, Faro, Portugal, 5 Algarve Biomedical Center (ABC), University of Algarve, Faro,
Portugal, 6 Marine Institute and Seaweed Research Group, Rinville, Oranmore, Co. Galway, Ireland, 7 Irish
Seaweed Research Group, Ryan Institute, National University of Ireland Galway, University Road, Galway,
Ireland, 8 Orthopaedic department, Royal Victoria Hospital, Belfast, United Kingdom, 9 School of Pharmacy,
Queen’s University Belfast, Belfast, United Kingdom
* s.a.clarke@qub.ac.uk
Abstract
Extracts and compounds derived from marine organisms have reportedly shown some oste-
ogenic potential. As such, these bioactives may aid in the treatment of musculoskeletal con-
ditions such as osteoporosis; helping to address inefficacies with current treatment options.
In this study, 72 fractions were tested for their in vitro osteogenic activity using a human foe-
tal osteoblast (hFOB) cell line and bone marrow derived mesenchymal stem cells (MSCs),
focusing on their cytotoxic, proliferative and differentiation effects. Extracts dissolved in
dimethyl sulfoxide and ethanol showed no significant osteogenic potential. However, two
extracts derived from powder residues (left over from original organic extractions) caused a
significant promotion of MSC differentiation. Bioactivity from powder residues derived from
the epiphytic red algae Ceramium pallidum is described in detail to highlight its treatment
potential. In vitro, C. pallidum was shown to promote MSC differentiation and extracellular
matrix mineralisation. In vivo, this extract caused a significant increase in opercular bone
growth of zebrafish larvae and a significant increase in bone density of regenerated adult
caudal fins. Our findings therefore show the importance of continued screening efforts, par-
ticularly of novel extract sources, and the presence of bioactive compounds in C. pallidum
extract.
Introduction
Both disability and mortality associated with osteoporosis are highly significant in developed
countries; exceeding the disease burden of common neoplastic disorders in Europe, except for
lung cancer [1]. Osteoporosis is associated with decreased bone formation by osteoblasts and
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increased bone resorption by osteoclasts, which lowers bone mass, reduces mineral content
and causes a breakdown of bone microarchitecture [2–4]. This results in weaker bone which is
more susceptible to fracture damage, particularly in postmenopausal women. All currently
available treatment options for osteoporosis have a variety of issues surrounding their efficacy
and suitability for long-term use. For example, bisphosphonates—a commonly prescribed
antiresorptive drug—are very effective at reducing fracture risk [5,6]. However, these drugs
mainly serve to limit further bone loss and cause only small increases in mineral density (2%
or less) [7], whilst also being associated with rare but severe side effects [8]. Alternatively, ana-
bolic treatments are less well developed, with teriparatide the only established treatment
option. Unfortunately, the daily injections required with this treatment are very expensive and
need to be maintained to aid long term bone formation [8,9]. As such, there is a need for novel
osteogenic treatments, which would ideally stimulate the recovery of bone mineral density and
structure. In addition to osteoporosis there are numerous other musculoskeletal conditions,
such as complex fracture and osteopetrosis, which would also benefit from new effective
treatments.
Marine organisms are a particularly interesting resource for novel drugs. These organisms
are subjected to an extreme range of environmental variables, which fuels their specialisation
and adaptation [10], along with the production of novel molecules/compounds. However,
screening efforts for most species remain in their infancy and the search for bioactives remains
firmly focussed in the anti-microbial and anti-cancer arenas. Despite this, there are still prom-
ising examples of marine invertebrate derived extracts and compounds which show osteogenic
activity. One pivotal example is nacre, the lustrous aragonitic layer of molluscan shells, which
was shown to significantly aid bone reconstruction of maxillary defects when mixed with the
blood of female patients [11,12]. This discovery helped to fuel interest in marine bioactives,
though current focus in this area has shifted onto other taxonomic groups. For instance, algae
show great bioactive diversity and excellent treatment potential, with fucoidan a particularly
well studied example. Derived from multiple taxa, such as brown macroalgae, this highly
sulphated and fucose rich polysaccharide inhibits osteoclast bone resorption and promotes
osteoblast activity, by activating ERK and JNK pathways [13]. As such, fucoidan shows osteo-
genic potential both in vitro and in vivo [14]–though it’s in vivo effects remain to be described
in detail.
In this study we aimed to address the limitations of current screening efforts by assessing
osteogenic activity from extracts of Irish marine organisms. These were derived from a wide
range of taxonomic groups–sampled from both shallow and deep-water environments on the
west coast of Ireland. Our hypothesis was that osteogenic bioactives were present in one or
more of the marine extracts tested in this study, with algal extracts being a likely candidate.
This is because previous literature has indicated algal extracts contain bioactive compounds
such as fucoidan [14] from brown macroalgae, floridoside [α-D-galactopyranosyl-(1–2)-L-
glycerol] from the red algae Laurencia undulata and mineralogenic compounds from green
macroalgae [15]. However, a diverse range of samples was tested, as research in this field is still
in its infancy and it was not known which species/groups would show greatest activity.
Extracts were dissolved in either dimethylsulfoxide (DMSO), ethanol or via an alkaline extrac-
tion and their proliferative and differentiative potential were assessed in vitro using human
bone-derived cell systems. One promising extract from the red algae Ceramium pallidum
(Naegeli ex Kuetzing) Maggs & Hommersand was tested in more detail, including in vivo
through operculum bone growth and caudal fin regeneration zebrafish models. It is hoped
that bioactives from this extract may be a future treatment option for musculoskeletal disor-
ders such as osteoporosis, leading to improved clinical outcomes and a better standard of
living.
Marine organisms and bone healing
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Materials and methods
Sample collection and extraction
Collection: due to the large number of fractions assessed in this study, sampling took place
over a prolonged time-period at multiple sites. Specimens were gathered as part of the Beaufort
Marine Biodiscovery Research programme, using a previously described strategy [16]. The
sample of C. pallidum, growing epiphytically on the brown alga Himanthalia elongata (L.) S.F.
Gray, was collected on 05.06.2012 in the lower intertidal at Finavarra, Co. Clare, Ireland. Sam-
ple processing and genetic identification followed methods given in Carson et al. [17]. A
voucher specimen was deposited at the herbarium of the National University of Ireland Gal-
way under the accession number GALW16211. The rbcL gene sequence of this specimen is
accessible from European Nucleotide Archive ENA or GenBank.
Original extraction: during extraction each specimen was processed using a modified in-
house method [16]. Firstly, each specimen was freeze-dried and milled into a fine powder. Five
grams of milled material was then mixed with 500 ml of dichloromethane (DCM), at 20˚C for
24 h. This suspension was filtered, and any remaining undissolved material was mixed with
500 ml of methanol for a further 24 h at 25˚C. This solution was also filtered and the remaining
powder residue collected, before the dissolved portions from each extraction were left to air-
dry. DCM and methanol portions were then mixed together, whilst the powder residue was
kept separately.
Secondary processing: DCM/methanol mixture was processed further by the addition of
either dimethylsulfoxide or ethanol at a concentration of 30 mg/ml. Extracts were then added
to culture media at a concentration of 0.1% for DMSO and 0.5% for ethanol. This gave final
extract concentrations for all assays ranging between 20 and 31.7 μg/ml for those dissolved in
DMSO and 150 μg/ml for those in ethanol (except for E-19: 20.8 μg/ml and E-22: 86 μg/ml).
Culture media was filtered (0.22 μm) before use. For the powder residue fractions, extracts
were either dissolved in water or a basic extraction was performed, based on a method adapted
from previous studies [18,19], via the addition of 0.1 M NaOH (30 mg/ml). Samples then
underwent 3 rounds of vortexing, sonication (25 min, 25˚C) and mixing (45 min, 37˚C). After-
wards, each was centrifuged twice, for 15 min at 3000×g, to separate out supernatant from
remaining undissolved powder. Supernatant was neutralised to approximately pH 7.5, via
addition of 0.5 M HCl. This extract solution was subsequently added to culture media (or zeb-
rafish system water), which was filtered (0.22 μm) before use. The concentration of powder
solutions in culture media or system water ranged between 0.1 and 10%, giving C. pallidum
extract concentrations of 15–1520 μg/ml. See Table 1 for a full list of those extracts tested in
this study and Fig 1 for a summary.
Cell culture–hFOB and MSC
The hFOB 1.19 (ATCC CRL-11372) cell line was cultured in T75 flasks and expanded by sub-
culturing (0.25% Trypsin EDTA, 1:4 slitting ratio). hFOBs were cultured in complete media
comprised of DMEM/HAM F12 (Sigma-Aldrich, UK) supplemented with 10% foetal bovine
serum (Sigma-Aldrich, UK) and 2 mM L-glutamine (PAA, UK). Cells were used between pas-
sages 6 and 10. MSCs were extracted from vertebral bone marrow samples collected by sur-
geons at the Royal Victoria Hospital, Belfast, during the placement of intervertebral screws.
After collection, samples were processed to extract the white blood cell-containing component,
which was subsequently cultured until 75% confluent. MSCs were cultured in α-MEM
(Thermo Fisher Scientific, UK) supplemented with 10% foetal bovine serum, 2 mM L-gluta-
mine and 100 U/ml pen-strep (all sourced from Thermo Fisher Scientific, UK). After initial
Marine organisms and bone healing
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Table 1. Summary of tested extracts/fractions.
Fraction Concentr- Extract effect on cell activity (hFOBs, MSCs)
number Common name Genera/Species/description ation (μg/ml) Cytotoxicity Proliferation Differentiation
DMSO dissolved extracts
D-01 Red algae Bonnemaisonia hamifera 5.83 Non-toxic Small decrease None
D-02 Coastal sponge Porifera demospongiae 5.97 Non-toxic None
D-03 Brown algae Bifurcaria bifurcata 5.82 Non-toxic None
D-04 Coastal sponge Porifera; Order Poecilosclerida 6.34 Non-toxic None
D-05(1) Coastal sea squirt Chordata; Class Ascidiacea 5.80 Non-toxic None
D-06 Coastal sponge Halichondria panicea 5.87 Non-toxic None
D-07 Red algae Anotrichium barbatum 5.71 Non-toxic None
D-08 Star fish Asterias rubens 6.00 Non-toxic None None
D-09(2) Coastal sea squirt Chordata; Class Ascidiacea 5.66 Non-toxic Small decrease Small decrease
D-10 Coastal sponge Haliclona indistincta 5.76 Non-toxic None
D-11 Red algae Griffithsia corallinoides 5.84 Non-toxic None
D-12 Red algae Bonnemaisonia hamifera 6.12 Non-toxic None
D-13 Coastal sponge Porifera; Order Poecilosclerida 6.16 Non-toxic None
D-14 Coastal sponge Dictyoceratid sponge 5.80 Non-toxic None
D-15 Green algae Ulva linza 5.76 Decreased None Small increase
D-16 Brown algae Cystoseira tamariscifolia 5.80 Decreased None
D-17 Red algae Polysiphonia elongata 6.12 Decreased Small decrease None
D-18 Brown algae Sargassum muticum 6.11 Decreased None
D-19 Coastal sponge Porifera; Family Suberitidae 5.96 Decreased None
D-20 Brown algae Desmarestia aculeata 5.90 Decreased Small decrease Increased
D-21 Red algae Polysiphonia stricta 5.72 Decreased Small decrease Decreased
D-22 Coastal sponge Polymastia boletiformis 5.98 Decreased None
D-23 Brown algae Sargassum muticum 5.85 Decreased None
D-24 Coastal sponge Suberites ficus 6.03 Decreased Small decrease Decreased
D-25 Coastal sponge Dysidea fragilis 5.91 Decreased None None
D-26(1) Tunicate Ascidian; Family Styelidae 6.03 Decreased None Increased
D-27 Coastal sponge Haliclona simulans 6.04 Decreased Small decrease None
D-28(2) Tunicate Ascidian; Family Styelidae 5.84 Decreased Small decrease None
D-29 Coastal sponge Haliclona indistincta 6.23 Decreased Small increase
D-30 Brown algae Cystoseira baccata 5.70 Decreased Small increase
D-31 Brown algae Desmarestia viridis 6.06 Decreased None
D-32 Brown algae Desmarestia ligulata 6.25 Decreased Small increase None
D-33 Coral Soft coral 5.36 Decreased Small increase None
D-34 Hydrozoan Hydrozoan 4.00 Decreased None None
D-35 Coastal sponge Sea fan; Paramuricea 6.06 Decreased None
D-36 Sea star Sea star 6.07 Decreased Small increase None
D-37 Brittle star N/A 5.33 Decreased Small increase None
D-38 Brown algae Cystoseira foeniculacea 6.20 Decreased Small increase
D-39 Brown algae Cystoseira nodicaulis 6.04 Decreased None None
D-40 Deep sea sponge Lissodendoryx diversichela 5.67 Decreased None None
D-41 Sea cucumber N/A 6.00 Decreased None
D-42 Sea fan N/A 6.00 Decreased None
Ethanol dissolved extracts
E-01 Star fish N/A 150 Small increase Decreased Decreased
E-02 Sea fan N/A 150 Non-toxic None
(Continued)
Marine organisms and bone healing
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growth, MSCs were expanded by subculturing (using 0.25% Trypsin-EDTA and a 1:4 splitting
ratio); no cells beyond passage 6 were used in experiments (see Figs 2 and 3 for results using
these cells).
Cytotoxicity–lactate dehydrogenase (LDH)
The CytoTox 96 Non-Radioactive Cytotoxicity Assay kit (Promega, UK) was used to quantify
levels of lactate dehydrogenase (LDH), an enzyme normally constrained to the cytoplasm of
healthy cells. Its release in the culture medium gives an indication of extract cytotoxicity.
hFOBs were plated at a density of 1 x 104 cells/cm2 and were given a 24 h attachment period
and 24 h with extract treatments, before conditioned medium was removed and LDH level
quantified according to the manufacturer’s protocol.
Table 1. (Continued)
Fraction Concentr- Extract effect on cell activity (hFOBs, MSCs)
number Common name Genera/Species/description ation (μg/ml) Cytotoxicity Proliferation Differentiation
E-03 Deep sea sponge Haliclona simulans 150 Non-toxic None
E-04 Soft coral Soft coral 150 Increase Decrease Decreased
E-05 Sea star Sea star 150 Non-toxic None Small increase
E-06 Sea star Cushion star fish 150 Non-toxic Decreased
E-07 Sea star N/A 150 Non-toxic None
E-08 Sea star Sea star 150 Non-toxic Decreased
E-09 Sea pen Sea pen 150 Non-toxic None
E-10 Sea star Cushion sea star 150 Non-toxic None
E-11 Sea fan Phanophathes sp. 150 Non-toxic None Decreased
E-12 Red algae Corallina elongata 150 Non-toxic None
E-13 Algae (griffithsia) Griffithsia corallinoides 150 Non-toxic None
E-14 Sea star Cushion sea star 150 increase None
E-15 Sea fan Pentaculacea 150 Non-toxic None
E-16 Deep sea sponge Haliclona indistincta 150 Non-toxic Decreased
E-17 Red algae Ceramium secundatum 150 Non-toxic Decreased Decreased
E-18 Brown algae Bifurcaria bifurcata 150 Toxic Decreased
E-19 Red algae Boergeseniella fructiculosa 20.8 Non-toxic Decreased None
E-20 Red algae Plocamium cartilagineum 150 Increase Decreased Decreased
E-21 Red algae Osmundea sp. 150 Decreased None Decreased
E-22 Brown algae Ectocarpales (Puncatria) 86 Decreased None Decreased
E-23 Sponge Cladostephus spongiosus 150 Non-toxic Decreased
E-24 Coral N/A 150 Non-toxic Decreased Decreased
E-25 Deep sea sponge Haliclona indistincta 150 Decreased None Decreased
Powder residue extracts
P-01 Coral Lophelia coral 1 small decrease None
P-02 Seaweed Percursaria percursa 1 small decrease Increased
P-03 Red algae Porphyra umbilicalis 1 small decrease Small decrease
P-04 Deep sea sponge Psolus squamatus 1 small decrease Increased
P-05 Red algae Osmundea sp. 1 small decrease Decreased
P-06 Red algae Ceramium pallidum Variable Increased
‘D’ indicates a fraction/extract dissolved in DMSO, ‘E’ indicates dissolved in ethanol and ‘P’ indicates a powder residue. (1) and (2) indicate separate samples from the
same species.
https://doi.org/10.1371/journal.pone.0207303.t001
Marine organisms and bone healing
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Cell proliferation–crystal violet
Extract concentrations were as follows: 1. 150 μg/ml (E-19: 20.8 μg/ml and E-22: 86 μg/ml) for
ethanol dissolved extracts and 2. 15, 75, 150, 760 and 1520 μg/ml for C. pallidum powder
extract. Controls were as follows: 1. 0.5% ethanol and 2. 1, 5 or 10% saline solution (control
presented as an average of these three treatments to ensure saline addition had no significant
effect). hFOBs were plated at a density of 1 × 104 cells/cm2 and MSCs at 2 × 104 cells/cm2. Sub-
sequently, each cell type was challenged by the extracts for 1, 4 or 7 days. Seven-day cultures
were re-fed once with treated media on day 4. Crystal violet staining was used to measure cell
proliferation, in a method similar to that of Kim et al. [13]. Briefly, cells were fixed at 25˚C for
30 min by the addition of 100 μl of 2% paraformaldehyde (Sigma-Aldrich, UK) solution (pH
6.8 in PBS). Cell monolayers were stained at 25˚C for 30 min, using 100 μl of crystal violet
solution (Sigma-Aldrich, UK) per well (0.1% in dH2O, filtered before use). Dye was extracted
Fig 1. Flow diagram of extracts tested. Diagram showing the results obtained from the screen of 72 extracts. Activity was defined as a significant increase in
proliferation or differentiation, which lead to powder extracts being identified as the most promising extract reserve. Ceramium pallidum is highlighted, as powder
extract from this species gave the best osteogenic result to date (increasing cell differentiation and cell/zebrafish mineralisation); as such it is discussed in greater detail in
the present study.
https://doi.org/10.1371/journal.pone.0207303.g001
Marine organisms and bone healing
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from monolayers by the addition of 100 μl of 1 M acidified methanol. Treatments were
blanked using acidified methanol and absorbance was measured at 585 nm, using a Multiskan
Spectrum microplate reader (Thermo Fisher Scientific, UK).
Cell proliferation–PicoGreen. The Quant-iT PicoGreen dsDNA Assay kit (Thermo
Fisher Scientific, UK) was used to quantify the amount of double stranded (ds) DNA present
within a sample, following manufacturer’s instructions, to determine proliferation for DMSO
dissolved extracts and to normalize alkaline phosphatase (ALP) results. For proliferation of
DMSO extracts concentrations ranged between 20 and 31.7 μg/ml, whilst control was 0.1%
DMSO, with a separate control included on each assay plate used (large extract number). Cells
Fig 2. In vitro effects of various extracts. (a, c, e) Proliferation of hFOBs at day 7 determined by PicoGreen assay. (a) Cells were challenged with either
DMSO dissolved fractions D-01 to D-42 (subset shown in figure, complete set presented in S1, S2 and S3 Figs) or control (0.1% DMSO). (c) Cells were
challenged with ethanol dissolved extracts E-01 to E-25 (subset shown in figure, complete set shown in S5 and S6 Figs) or control (0.5% EtOH). (e) Cells
were challenged with control (saline solution–average of proliferation values for treatments between 1–10% concentration) or powder extracts P-01 to
P-05, dissolved in a saline solution and at concentrations in cell media of 1, 5 or 10%. Cell proliferation, as a percentage of control, is presented as mean
+/- standard deviation (SD), (n = 3 or 4). (b, d, f) ALP activity of MSCs at day 7 normalised to DNA concentration, treated with the same extract subset
or control as detailed previously for DMSO (b), ethanol (d) and powder extracts (f). Relative ALP activity is presented as the mean +/- SD (n = 3). �
indicates a statistically significant difference (p<0.05) compared to the relevant control–(a) included 3 separate controls as it combines data from 3
individual experiments.
https://doi.org/10.1371/journal.pone.0207303.g002
Fig 3. In vitro osteogenic effects of C. pallidum extract. (a)-(c) Proliferation of MSCs at day 1 (a), 4 (b) and 7 (c) using crystal violet assay. Cell number is presented as
mean +/- SD, (n = 4). (d) Differentiation of MSCs at day 14, presented as relative ALP activity, normalised to DNA content–mean +/- SD (n = 4). (e) In vitro
mineralisation of MSCs at day 21. AR-S concentration is presented as mean +/- SD (n = 4). (f) Micrographs of MSC monolayers stained with AR-S, for control day 21
and C. pallidum at a 150 and 300 μg/ml concentration (black rectangle is a 1 mm scale for each micrograph). � indicates a statistically significant difference (p<0.05)
compared to the relevant control.
https://doi.org/10.1371/journal.pone.0207303.g003
Marine organisms and bone healing
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were challenged by extracts for 1, 4 or 7 days, medium was removed and the cells were washed
twice with PBS or alkaline buffer solution (5 M NaCl, 1 M Tris-Cl pH 9.5, 1 M MgCl2). 250μl
of lysis buffer (0.1 or 0.2% Triton X-100 (Sigma-Aldrich, UK) in PBS or alkaline buffer) was
added to each well which was then subjected to at least 1 cycle of freeze (-80˚C) and thaw
(+37˚C). This ensured that cell membranes were completely lysed through ice crystal forma-
tion, therefore releasing all dsDNA into solution. Sample wells were then mixed and 50 μl of
each lysate was added to assay plates in duplicate. A standard curve of 1 mg DNA/ml, 100 ng/
ml, 10 ng/ml, 1 ng/ml and 0 ng/ml was added in duplicate to each assay plate. Finally, 50 μl of
test solution was added to all wells and fluorescence levels were read at excitation 480 nm,
emission 520 nm using a GENios microplate reader (TECAN, Austria).
Cell differentiation. MSCs were plated at a density of 1 × 104 cells/cm2 in 96-well plates
and cultured with extracts dissolved in osteogenic media (complete media supplemented with
50 μM ascorbate-2-phosphate, 10 μM β-glycerol phosphate and 0.01 μM dexamethasone, all
sourced from Sigma-Aldrich, UK) for 7 or 14 days. Extract concentrations and control solu-
tions were the same as those detailed previously, except for the use of osteogenic (rather than
complete) media. Extract containing media was replaced twice weekly. Alkaline phosphatase
(ALP) activity was measured following p-nitrophenyl phosphate level. Briefly, at each time
point cells were: 1. washed with an alkaline buffer solution (5 M NaCl, 1 M Tris-Cl pH 9.5, 1
M MgCl2), 2. lysed by addition of 250 μl of alkaline buffer containing 0.2% Triton X-100, 3.
left to gently mix for 20 min on ice and 4. stored at -80˚C. Upon defrosting, 50 μl from each
cell extract was added to a test plate in duplicate and supplemented with 200 μl of conditioned
medium, consisting of alkaline buffer solution (Sigma-Aldrich, UK) and p-nitrophenyl phos-
phate substrate (Sigma-Aldrich, UK). Each test plate was then covered in foil and incubated at
37˚C for 30 min, allowing the coupled enzymatic reaction to proceed. The reaction was
stopped by the addition of 50 μl of 3 M NaOH to each well, before absorbance was read at 450
nm using a GENios microplate reader (TECAN, Austria). Finally, ALP activity was normalised
to DNA concentration, determined via PicoGreen assay to account for variations in cell
proliferation.
Extracellular matrix mineralisation. MSCs were grown to 75% confluency in 24-well
plates, before osteogenic media and C. pallidum extracts at 15, 75, 150 and 300 μg/ml concen-
trations were added—for 21 days. Medium was replaced twice weekly. Alizarin red S (AR-S;
Sigma-Aldrich, UK) staining was used to detect mineralisation of the extracellular matrix pro-
duced by mature osteoblasts. At each time point, cells were washed 3x with PBS and fixed with
4% paraformaldehyde (0.25 ml) at 25˚C for 1 h. Fixative was then removed and wells washed
3x with dH2O. 40 mM AR-S, adjusted to pH 4.2 using ammonium hydroxide, was added to
each well (0.5 ml). Plates were left to stain at 25˚C for 15 min, with gentle agitation on an
orbital shaker. Staining solution was discarded and each well was washed again, 4x with dH2O,
before being left to air-dry. Finally, wells were de-stained using a solution of 10% cetylpyridi-
nium chloride (Sigma-Aldrich, UK) in sodium phosphate (pH 7.0). A 100 μl aliquot of each
treatment was collected, transferred to a 96-well plate and then used for measuring absorbance
at 550 nm. Absorbance readings were then converted to AR-S content values via a standard
curve equation (R2 = 0.99) made using a dilution series of AR-S stock solution.
in vivo operculum model. For a more detailed method see Tarasco et al. [20] (see Fig 4
for visualisation of method). Briefly, sexually mature AB wild-type strain zebrafish were mated
and fertilised eggs were collected and transferred to a 1-L container. Eggs were then placed in
an incubator (28.0 ± 0.1˚C) for 72 h with a photoperiod of 14–10 h light-dark. At three days
post-fertilisation (dpf), viable larvae were transferred into 6-well plates. Each well housed 15
larvae in 10 ml of system water, to which extracts were added. Concentrations of C. pallidum
extract included 30, 150, 760 and 1520 μg/ml. Controls included a standard control group
Marine organisms and bone healing
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Fig 4. In vivo osteogenic effects of C. pallidum extract–operculum model. (a) Schematic detailing the method used for the operculum bone growth model. (b)
Mortality rates of zebrafish larvae during in vivo experimentation. (c) Picture of a control alizarin red-S stained zebrafish larvae at 6 dpf showing head and operculum
area evaluated through morphometric analysis. (d) Picture of a stained larvae treated with 760 μg/ml C. pallidum. (e) Operculum growth for C. pallidum treatments.
Control was fish water with 10% dH2O. A 0.2% EtOH control corresponded to the positive calcitriol control. Corrected operculum area is presented as mean +/- SD
(n = 15).
https://doi.org/10.1371/journal.pone.0207303.g004
Marine organisms and bone healing
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(plain water), a positive control of 20 pg/ml calcitriol (Tocris Bioscience) dissolved in ethanol,
as well as a negative control for this group—containing only 0.2% ethanol. 70% of treatment
water was replaced daily during the three-day exposure period. Subsequently, larvae were
stained in excess AR-S solution (0.01%, pH 7.4) for 15 min, washed twice in system water (5
min) and then sacrificed (1:1000 dose of 2-phenoxyethanol; Sigma-Aldrich, UK). Larvae were
sacrificed in batches of 15 individuals and imaged directly after euthanasia (via lateral place-
ment on a 2% agarose gel). An MZ 7.5 stereomicroscope (Leica, Wetzlar, Germany) was used,
equipped with a green light filter (λex = 530–560 nm and λem = 580 nm) and a black-and-white
F-View II camera (Olympus, Hamburg, Germany). Images were subsequently analysed using
Image J 1.49 (Wayne Rasband, Bethesda) software. Ratios comparing the head and operculum
area were then calculated and given as a percentage of the control.
in vivo caudal fin regeneration model. Caudal fin regeneration experiments used a
method modified from Cardeira et al. [21] (see Fig 5 for visualisation of method). Adult wild-
type AB zebrafish aged 3–5 months were used in all experiments. Individuals were anesthetised
via submersion in a water bath containing MS222 (Sigma-Aldrich, St. Louis, MO) and subse-
quently quickly dried and weighed. Injection volumes were calculated using each individual
weight, based on a target addition of 3 μl solution per 100 mg fish weight. Treatment solutions
included either a saline solution (control) or a saline dissolved mixture of C. pallidum powder
residue at a concentration of 1.56 μg per mg fish weight. Individuals were then amputated 1–2
segments anterior to the bifurcation of the most peripheral branching lepidotrichia. After
amputation, treatments were administered via intraperitoneal injection and individuals were
then placed into plastic containers holding 900 ml of water, at a density of five fish per con-
tainer. Container water was replaced daily and heated to 33˚C to accelerate the regenerative
process [22] and fish were fed twice daily with dried food. After a five-day period, individuals
were live-stained by submersion in 200 ml of 0.01% AR-S solution for 15 min, then washed for
5 min before being anesthetized in a solution of MS222 [23]. Individuals were then immedi-
ately imaged, using the same camera system as described for the larvae. Fluorescence and
bright field images were collected for each individual, using an exposure of 500 ms. Images
were then analysed using Image J 1.49 software, allowing a number of measurements to be
taken. Total regenerated area (REG) was measured from the amputation plane to distal end of
the fin and was corrected with the stump width (STU). Mean ray width (RAY) was determined
as the mean width of rays at the first intersegment joint below the amputation plane. Real min-
eral area (RMA) was measured after applying a colour threshold which selected only the min-
eralised red areas. Finally, the intensity of calcium staining was assessed using the intensity of
pixels within mineralised regions (using the YUV colour model and intensity values in the 15–
254 arbitrary unit range).
Ethical approval. All methods involving human tissue samples were carried out in accor-
dance with the Human Tissue Act. Ethical approval was granted by the North East-Tyne and
Wear South Research Ethics Committee (REC ref 15/NE/0250), specifically for the use of
human derived tissue from NHS patients. Informed consent was obtained from all patients
who provided samples for use in this work.
All experiments involving zebrafish were completed in Portugal. Only qualified operators
were involved in animal handling and experimentation, having been legally accredited by the
Portuguese Direc¸ão Geral de Alimentac¸ão e Veterina´ria (DGAV). All experimental procedures
involving zebrafish followed the EU (Directive 86/609/CEE and 2010/63/EU) and National
(Portaria n.˚ 1005/92 de 23 de Outubro; Portaria n.˚ 466/95 de 17 de Maio; Portaria n.˚ 1131/
97 de 7 de Novembro) legislation for animal experimentation and welfare. Experimental pro-
cedures involving zebrafish were performed under authorization (0421/000/000) from the
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DGAV, complying with the decreto de lei 113/2013 de 7 de Agosto, from the Portuguese
legislation.
Statistical analysis. Prism version 6.00 (GraphPad Software, Inc. La Jolla, CA) software
was used for statistical analysis. Datasets were tested for normality using D’Agostino-Pearson
and Shapiro-Wilk test. Statistical comparisons were analysed with one-way ANOVA and post-
hoc with Dunnett’s multiple comparison test. For zebrafish results the same analysis was con-
ducted, though positive control comparisons were made using unpaired t-tests with Welch’s
correction. For all tests, a p<0.05 was considered statistically significant. Sample sizes can be
found in each figure legend.
Results
Screening detailed within this manuscript first focused on marine organism extract material
dissolved in DMSO, before being expanded to include ethanol dissolved extracts and powder
residues. Throughout this process (summarised in Fig 1, more detailed summary in Table 1)
powder residue material showed most promise through its effect on cell differentiation. How-
ever, Ceramium pallidum extract was selected as having the best overall osteogenic potential–
increasing cell differentiation and mineralisation, as well as promoting mineralisation in vivo.
For all assays, time points appropriate to the mechanism being tested were chosen, such as
cytotoxicity at day 1 and differentiation at day 7.
Solvent fractions and powder derived extracts
DMSO was chosen as a solvent for this screen as it is the most commonly used solvent in
screening work and is effective at dissolving a wide range of compounds [24]. However, it was
limited to a 0.1% concentration to avoid changes in cell membrane properties and cell mor-
phology [25], giving an effective concentration ranging between 20 and 31.7 μg/ml for each
extract. Fractions dissolved in DMSO had little effect on hFOB proliferation [Fig 2(A)]. At day
7, fractions D-01, 09, 17 and 27 caused small but significant decreases in cell proliferation rela-
tive to control (DMSO), whilst D-33 caused a small significant increase (cell proliferation:
0.71, control: 0.55, p = 0.047). This subset reflects the trends of all DMSO dissolved extracts
(total of 42), as only small deviations in proliferation were seen for all extracts tested (see S1,
S2 and S3 Figs). A similar trend was also seen for day 7 MSC differentiation [Fig 2(B)]; MSCs
were used as they were shown during preliminary tests to have a more sensitive differentiation
response. There were no significant increases in alkaline phosphatase (ALP) activity, though
D-15, 20 and 26 were slightly higher than control. Decreased activity was more common, of
which D-09 and particularly D-21 and 24 were significant. Lactate dehydrogenase (LDH) cyto-
toxicity results (presented in S4 Fig) showed that none of the extracts were toxic, whilst D-15-
42 actually caused small decreases in cell death levels.
Ethanol was subsequently chosen for use as it was shown to have less of a toxic effect on
hFOBs than DMSO during preliminary testing, being tolerated up to a 0.5% level. This allowed
a concentration of 150 μg/ml to be reached for each extract (except for E-19: 20.8 μg/ml and E-
22: 86 μg/ml, as less extract material was available for testing). Ethanol dissolved extracts had
similar effects as those in DMSO, mainly serving to decrease hFOB cell proliferation [Fig 2
Fig 5. In vivo osteogenic effects of C. pallidum extract–caudal fin model. (a) Schematic detailing the method used for the caudal fin model. (b) Histogram showing
pixel intensity frequencies in classes 7–13 and 14–20. (c) Picture of alizarin red-S stained caudal fin (red channel) from a control individual 120 hpa. (d) Picture of
stained caudal fin from an individual treated with C. pallidum at 1.56 μg per mg fish weight (same for all treated individuals), 120 hpa. (e) Average percentage frequency
(n = 5) for control and C. pallidum treated individuals within pixel intensity classes of 7–13 and 14–20. (f) Degree of osteogenesis at 120 hpa. (g) Degree of regeneration
at 120 hpa. � indicates a statistically significant difference (p<0.05) compared to the relevant control.
https://doi.org/10.1371/journal.pone.0207303.g005
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(C)]. Of the subset shown, all decreases were significant—including E-01, 04, 17, 19, 20, 24 and
25. Remaining extracts were comparable in value to the control (EtOH), except for E-05 which
was slightly increased. This subset again reflects the trends of the whole extract set tested (total
of 25; complete set is presented in S5 and S6 Figs). MSC ALP activity [Fig 2(D)] was similar to
that of hFOB proliferation, with E-05 again the only extract showing an increase compared to
control. E-10 and E-19 had no effect, whilst all remaining extracts caused significant reduc-
tions. For cytotoxicity, E-01, 04, 14 and 20 caused small increases in LDH enzyme activity lev-
els, indicating increased cell death, but these were small and therefore unlikely to be toxic (S7
Fig). Alternatively, E-21, 22 and 25 decreased cell death, whilst the remaining treatments were
all non-toxic.
Due to the sensitivity of the LDH assay to dissolved particulate matter, cytotoxicity results
were not reliable for powder extract treatments and have therefore not been included in the
supplementary material. Furthermore, powder extracts had a very limited effect on hFOB pro-
liferation [Fig 2(E)]. All 1 and 5% treatment concentrations were comparable to control,
except for P-05 which was significantly reduced at 5% (p< 0.0001). Apart from P-03, all other
powder treatments significantly reduced proliferation at their maximum concentration of
10%. MSC ALP results used a lower concentration range of 0.1, 1 and 5% [Fig 2(F)]. P-01 had
no effect other than a slight reduction in ALP activity, as did P-03 which was significant at 5%;
whilst P-05 was significantly reduced at both 1 and 5%. However, extracts P-02 and 04 caused
a marked increase in ALP activity at 1 and 5% concentrations. Each peaked at 1%, though P-04
caused a greater effect than P-02—with an approximate 2.5-fold increase in ALP activity com-
pared to control.
Mineralogenic effects of C. pallidum powder fraction in vitro
Effect of the powder fraction from Ceramium pallidum (P-06) on MSC cell proliferation
changed slightly between timepoints [Fig 3(A)–3(C)]. At all timepoints (day 1, 4 and 7) the
greatest concentration, 1520 μg/ml, caused a significant reduction in proliferation to a level
approximately half that of the control. At day 1, cell proliferation was also reduced upon expo-
sure to 760 μg/ml of P-06, though this effect was lost at day 4. By day 7, a bell-shaped response
was seen, with the 150 μg/ml concentration stimulating the most cell proliferation, which
slightly exceeded that of the control. 15 and 1520 μg/ml concentrations were significantly
reduced, though this was most pronounced for the 1520 μg/ml treatment. Also at day 7, ALP
activity of MSCs was significantly increased at a 150 μg/ml concentration [Fig 3(D)], whilst
remaining concentrations were similar in value to control. 1520 μg/ml was an exception to
this, as no ALP activity was detected. Levels of mineralisation, expressed as the amount of aliz-
arin red-S bound to the mineral deposited in the extracellular matrix (ECM) of MSCs, were
determined at day 21 [Fig 3(E)]. A clear trend was apparent, as each concentration of C. palli-
dum caused a marked significant increase (p< 0.0001 for all) in mineralisation level. For the
15, 75 and 300 μg/ml concentrations these increases were almost three times greater than the
control value. However, the 150 μg/ml treatment performed best, causing a 5-fold increase in
ECM mineralisation.
Osteogenic effect of C. pallidum powder fraction in vivo
During the treatment period there were small losses of 1 or 2 larvae in each treatment [Fig 4
(B)]. For example, 1 sample was lost in each of the 30 and 1520 μg/ml treatment groups, due to
damage during placement for imaging. There was also one large mortality event 72 hours after
initial exposure in the 150 μg/ml treatment group, whereby 11 larvae died—accounting for
73% of the population (15 larvae total); see discussion for explanation of this.
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Overall, C. pallidum caused a significant increase of larvae operculum growth compared to
the control, ranging from 48.4% ± 21.9% at a 30 μg/ml concentration, to a maximum of 86.1%
± 30.0% at a 760 μg/ml concentration [Fig 4(E)]. The highest treatment concentration,
1520 μg/ml, had a slightly lower—but still significant—average size increase of 78.5 ± 23.7%.
Calcitriol, as a positive control, significantly increased operculum size in the order of
29.6 ± 31.6%, relative to the 0.2% ethanol vehicle control. Images of stained zebrafish larvae
illustrate this effect, highlighting the increase in operculum size with C. pallidum treatment
(760 μg/ml) compared to control.
In adults, C. pallidum extract was used at 1.56 μg per mg fish weight. Extract treatment
caused a slight increase in osteogenesis of the regenerating fin area 120 h post-amputation
(hpa), though this was not significantly different from control [Fig 5(F)]. Alternatively, regen-
eration was slightly decreased upon C. pallidum treatment, though also not to a significant
degree [Fig 5(G)]. Pixel intensity formed two very distinct frequency curves between control
and C. pallidum treatments [Fig 5(B)]. For the control, mean frequency peaked in the low
intensity pixel classes (7–13), whereas C. pallidum was spread more evenly–having a greater
representation in the high intensity classes (13–19). Comparing the average percentage fre-
quency between the two classes, C. pallidum was shown to have fewer low intensity pixels and
more high intensity ones compared to control, both of which were significantly different [Fig
5(E)].
Discussion
This study aimed to screen a wide range of marine organisms, sourced from the west coast of
Ireland, for their osteogenic activities (as summarised in Fig 1 and Table 1); culminating in the
identification of an extract of C. pallidum, which had strong in vitro and in vivo mineralogenic
effects. The approach used was fairly novel, as screening efforts are still in their infancy and
tend to focus on identifying active compounds from one organism [26] or high-throughput
screening of many small molecules [27,28]. Specifically, a hFOB cell line was chosen to screen
for initial cytocompatibility by determining toxicity and extract effects on cell proliferation.
hFOBs benefit from being easily sourced whilst maintaining key osteoblast markers and char-
acteristics [29,30]. However, preliminary testing showed MSCs to have a greater and more sen-
sitive differentiation response than hFOBs, and these were therefore used to determine
osteogenic differentiation potential of promising extracts. During the screening process crite-
ria used to identify ‘active’ extracts were lack of toxicity and promotion of osteoblast activity.
This promotion could be of either proliferation or differentiation, as either characteristic
would be beneficial in osteoporosis or fracture treatment; by increasing the size of the active
cell component or promoting cell maturation. Extracts were also deemed active if decreased
proliferation was coupled with increased differentiation. This is because osteoblasts undergo a
sequential development, reducing their proliferation during differentiation towards the
mature phenotype [31].
The first 42 extracts screened covered a wide range of taxa, though were mainly comprised
of red, green and brown algae, as well as sponges (see supplementary data). As is common in
screening work, DMSO was used to dissolve extracts at a maximum solvent concentration of
0.1% [24,25]. The low LDH cytotoxicity values for each treatment confirmed DMSO was toler-
ated by cells at this level, and indicated all extracts were non-toxic. The relatively low extract
concentration may explain the limited effects seen on measures of cell activity–as neither
hFOB proliferation nor MSC differentiation varied greatly from control values. Of those devia-
tions seen, most were decreases in proliferation–whilst any increases were not large enough to
imply future treatment potential. For differentiation, alkaline phosphatase (ALP) activity was
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investigated as it is an established early marker of cell differentiation—indicating osteopro-
genitor cells are starting to form more mature osteoblasts [32]. However, no significant
increases in ALP activity were seen with any extract treatment, indicating no stimulation of
cell maturation.
As osteogenic activity was yet to be established a further 25 extracts were tested, though
each was dissolved in ethanol rather than DMSO. As ethanol was tolerated up to a 0.5% level,
this allowed a greater concentration of extracts to be tested with cells (approximately 150 μg/
ml). However, despite this greater concentration extracts performed similarly to those dis-
solved in DMSO, mainly serving to decrease hFOB proliferation. One extract, E-05 (sea star,
species unknown), did increase both hFOB proliferation and MSC differentiation–though not
to a significant degree. This lack of activity is not surprising, as most similar screening exer-
cises within this field only find a small number of active ‘hits’ in amongst many more inactive
compounds. For example, one study carried out a high throughput chemical screen of 45,000
small molecules, finding only two series of small molecules with potent osteogenic activity
[28].
The same extraction method, utilising dichloromethane and methanol, was used to produce
material which was then dissolved in either ethanol or DMSO–producing final fractions for
testing. As no substantial osteogenic potential was seen, the left-over material that did not dis-
solve in either dichloromethane or methanol–termed ‘powder extracts’ (due to their consis-
tency)–was also tested. These extracts were added to treatment media as either a saline or
water dissolved mixture, meaning solvent toxicity was not an issue and high extract concentra-
tions could therefore be achieved. Powder extracts had little effect on hFOB proliferation, as
with extracts dissolved in DMSO and ethanol. However, pronounced increases in MSC ALP
activity with P-02 and P-04 treatments indicates these two extracts contain bioactives able to
stimulate cell differentiation. P-02 extract was derived from the green seaweed species Percur-
saria percusa (C. Agardh) Rosenvinge, whilst P-04 was from the deep-sea sponge Psolus squa-
matus (O.F. Mu¨ller 1776). This positive result prompted further testing of seaweed, sponge
and alga-derived powder material in both in vitro and in vivo assays, with one species in partic-
ular–the epiphytic red alga Ceramium pallidum (extract P-06)–showing strong bioactivity.
Bioactivity for this species has been described in detail within the present study, to further
highlight the osteogenicity of powder extracts and the importance of continued screening
efforts.
There are limited reports mentioning C. pallidum, and none have investigated the osteo-
genic capacity of extracts from this species. MSCs were solely used for more detailed screening
of promising extracts, as they are more representative of the cells within the human body [33],
giving a better indication of treatment potential. Lack of proliferative effect separates C. palli-
dum extract from other algae-derived extracts, which do stimulate MSC proliferation, such as
fucoidan [13] and the total algal extract from Scytosiphon lomentaria (Lyngbye) Link [34]. The
increase of ALP activity in MSCs treated with 150 μg/ml C. pallidum indicates that the extract
promotes cell differentiation at this optimum concentration. Lower levels had no effect, whilst
the lack of activity seen with 1520 μg/ml indicates a complete suppression of ALP activity. This
is unlikely to be related to toxicity, as proliferation was reduced but still evident at 1520 μg/ml.
Instead it may indicate the presence of compound/molecule which inhibits differentiation at a
high concentration. As previously mentioned, proliferation is often reduced during osteoblast
differentiation and maturation [31], which may explain the lack of proliferative effect seen–an
idea supported by similar work. For example, the aforementioned floridoside from the red
algae Laurencia undulata Yamada had no significant effect on the degree of cell proliferation,
but strongly increased cell differentiation and eventual mineralisation [35]. However, it should
Marine organisms and bone healing
PLOS ONE | https://doi.org/10.1371/journal.pone.0207303 November 28, 2018 16 / 22
be noted that extracts which promote cell growth can still enhance differentiation, as with
fucoidan [13].
Once mature, osteoblasts produce factors which control mineral production [36], leading
to the formation of a mineralised extracellular collagen matrix and eventually new bone mate-
rial [37]. Therefore, an extract which promotes differentiation would also be expected to
enhance mineralisation level, as C. pallidum did in the present study. Here, extract inclusion
caused a significant promotion of MSC mineralisation, particularly at 150 μg/ml, indicating
early cell differentiation effects are maintained and lead to a greater degree of cell maturation
by day 21. These results are again supported by similar reports of activity from osteogenic
compounds and extracts, such as the aforementioned floridoside [35] and fucoidan. Fucoidan
in particular is reported to cause promotions of ALP and mineralisation level that are tightly
correlated [14,38]. Furthermore, whole extracts are also reported to stimulate osteoblast matu-
ration, such as those derived from the halophyte plant Salicornia herbacea L. [39] and the
brown algae Sargassum horneri (Turner) C.Agardh [40].
Based on in vitro data, C. pallidum appears to be a non-toxic extract, containing bioactive
components able to stimulate osteoblast maturation and mineralisation. However, it was also
important to assess if this osteogenic effect was maintained within a whole organism, to better
indicate future treatment potential. Zebrafish was chosen as a model organism due to its many
similarities with mammals regarding bone, including similar structures, regulators of bone for-
mation and developmental processes [41]. Two systems were used to look at different aspects
of skeletal formation: 1. an operculum-based system in larvae to measure bone growth, and 2.
a fin-regeneration model in adult fish to measure bone regeneration. Firstly, the operculum
system is particularly reliable and robust, allowing rapid detection of osteogenic, anti-osteopo-
rotic and osteotoxic activity [20]. In the present study, one large mortality event did occur 72
hours post treatment in the 150 μg/ml group. Whilst concerning, this event is unlikely to indi-
cate extract toxicity, considering it was limited to one treatment well and not seen when indi-
viduals were exposed to higher concentrations. Instead it is likely due to experimental
mishandling and this treatment will be repeated in future studies to rule out any toxic effects
of this particular concentration. Otherwise, C. pallidum had a very notable effect on operculum
growth, causing large size increases over the 3-day growth period. This correlates well with in
vitro data, though a higher concentration was required to fully promote operculum growth.
However, this was understandable as treatments were applied systemically, meaning they had
to be ingested or adsorbed through the skin [42]. Interestingly, even low concentrations still
gave an effect equal to, or exceeding, the positive control calcitriol–a known enhancer of oper-
culum [20] and skeletal growth [43]. The outperformance of calcitriols osteogenic effect by C.
pallidum extracts demonstrates the strength of its anabolic effect, suggesting its osteogenic
response may be maintained in mammals–such as rat and rabbit models of bone formation.
Adult individuals did not respond as obviously to C. pallidum treatment as larvae, though
measurements of pixel intensity indicated brighter pixels and therefore a stronger staining in
bony rays regenerated in fish exposed to the red algae extract [21]. This indicates that, relative
to control, C. pallidum extract treatment was promoting the bone density of the regenerated
rays, correlating with the previous in vitro and in vivo operculum effects seen. The slight
increase in osteogenesis and decrease in regeneration supports this effect, though these were
not significant in size. The reduced response in adults is likely due to differences in exposure
method, as individuals were injected with treatments rather than being immersed in them.
This injection was limited to a 3 μl volume per 100 mg fish weight, reducing the effective
extract concentration that could be achieved. Furthermore, it meant individuals were treated
only once during the 5-day regeneration period, rather than having constant exposure as with
other uses of this model [21] and the larval operculum system.
Marine organisms and bone healing
PLOS ONE | https://doi.org/10.1371/journal.pone.0207303 November 28, 2018 17 / 22
In general, powder extracts were more successful than fractions dissolved in DMSO and
ethanol, which may have been due in part to the use of a non-toxic solvent and the ability this
afforded to use higher treatment concentrations. However, these fractions do contain different
compounds and therefore it is also not unreasonable to suggest that it is something specific in
their composition that is responsible for the increased bioactivity in these assays. As all pow-
ders were water soluble this could suggest the active component(s) was a polar molecule, such
as a protein with exposed groups and a high dipole moment. If proteinaceous, bioactives in
those powders treated with alkaline extraction would likely be degraded, forming small-chain
peptides–or actives could instead be formed from more stable glycoproteins. Detailed chemical
analysis would be required to confirm the bioactive component of promising extracts, though
this was not undertaken as part of the current study. For screening efforts such analysis was
unfeasible—given the number of extracts tested—and unnecessary, as none displayed signifi-
cant osteogenic activity. For C. pallidum, some preliminary chemical analysis has been con-
ducted–which indicated protein and a low level of polysaccharides to be present in the extract.
Red algae are mainly comprised of protein (up to 47% of their dry matter), and often contain
high mineral and polysaccharide levels [44]. Though red algal-derived minerals–like Aqua-
min–are known to have an osteogenic effect, C. pallidum is a non-mineralising species [45].
Furthermore, red algal cell wall sulphated polysaccharides also have no reports of osteogenic
potential [46]. This leaves proteinaceous material most likely as an active component, or per-
haps a small-chain peptide, glycoprotein or even a mixture of different bioactives. Future clini-
cal use of this bioactive material is feasible, considering the worldwide abundance of the
Ceramium genus [47], its fast growth rates and the relative ease of sourcing these shallow
water eukaryotes.
Conclusions
This work detailed screening efforts focused on discovering novel osteogenic potential in
extracts derived from Irish marine organisms. Despite testing many extracts dissolved in
DMSO and ethanol it was extraction of powder residue material which showed most promise–
highlighting the need for continued screening efforts from different sources. Powder extract
from C. pallidum in particular showed excellent in vitro and in vivo osteogenic potential, and
may present a future therapeutic option for the treatment of osteoporosis and other musculo-
skeletal conditions. Further work will involve elucidating the exact bioactive component of
this extract and its mechanism of effect.
Supporting information
S1 Fig. hFOB proliferation with DMSO dissolved extract set 1. Proliferation of hFOBs at
day 4 (a) and 7 (b) calculated via PicoGreen assay. Cells were challenged with DMSO dissolved
extracts D-01 to D-14. DMSO was included at 0.1%, giving extract concentrations ranging
between 20 and 31.7 μg/ml. Cell proliferation, as a percentage of control, is presented as mean
+/- SD, (n = 4). � indicates a statistically significant difference (p<0.05) compared to the rele-
vant control.
(TIF)
S2 Fig. hFOB proliferation with DMSO dissolved extract set 2. Proliferation of hFOBs at
day 4 (a) and 7 (b) calculated via PicoGreen assay. Cells were challenged with DMSO dissolved
extracts D-15 to D-28. DMSO was included at 0.1%, giving extract concentrations ranging
between 20 and 31.7 μg/ml. Cell proliferation, as a percentage of control, is presented as mean
+/- SD, (n = 4). � indicates a statistically significant difference (p<0.05) compared to the
Marine organisms and bone healing
PLOS ONE | https://doi.org/10.1371/journal.pone.0207303 November 28, 2018 18 / 22
relevant control.
(TIF)
S3 Fig. hFOB proliferation with DMSO dissolved extract set 3. Proliferation of hFOBs at
day 4 (a) and 7 (b) calculated via PicoGreen assay. Cells were challenged with DMSO dissolved
extracts D-29 to D-43. DMSO was included at 0.1%, giving extract concentrations ranging
between 20 and 31.7 μg/ml. Cell proliferation, as a percentage of control, is presented as mean
+/- standard deviation SD, (n = 4). � indicates a statistically significant difference (p<0.05)
compared to the relevant control.
(TIF)
S4 Fig. hFOB cytotoxicity results for DMSO dissolved extracts. Cytotoxicity results (LDH
assay) for hFOBs at day 1. Cells were challenged with DMSO dissolved extracts D-01 to D-14
(a), D-15 to D-28 (b) and D-29 to D-43 (c). DMSO was included at 0.1%, giving extract con-
centrations ranging between 20 and 31.7 μg/ml. Cell death is presented as mean +/- SD
(n = 4). � indicates a statistically significant difference (p<0.05) compared to the relevant con-
trol.
(TIF)
S5 Fig. hFOB proliferation results for ethanol dissolved extract set 1. Proliferation of
hFOBs at day 4 (a) and 7 (b) calculated via crystal violet assay. Cells were challenged with etha-
nol dissolved extracts E-01 to E-13 or control (EtOH). Ethanol was included at a 0.5% concen-
tration, giving extract concentrations of 150 μg/ml. Cell proliferation, as a percentage of
control, is presented as mean +/- SD, (n = 4). � indicates a statistically significant difference
(p<0.05) compared to the relevant control.
(TIF)
S6 Fig. hFOB proliferation results for ethanol dissolved extract set 2. Proliferation of
hFOBs at day 4 (a) and 7 (b) calculated via crystal violet assay. Cells were challenged with etha-
nol dissolved extracts E-14 to E-25 or control (EtOH). Ethanol was included at a 0.5% concen-
tration, giving extract concentrations of 150 μg/ml (except for E-19: 20.8 μg/ml and E-22:
86 μg/ml). Cell proliferation, as a percentage of control, is presented as mean +/- SD, (n = 4). �
indicates a statistically significant difference (p<0.05) compared to the relevant control.
(TIF)
S7 Fig. hFOB cytotoxicity results for ethanol dissolved extracts. Cytotoxicity results (LDH
assay) for hFOBs at day 1. Cells were challenged with EtOH dissolved fractions E-01—E13 (a)
and E-14—E-25 (b). Ethanol was included at a 0.5% concentration, giving extract concentra-
tions of 150 μg/ml (except for E-19: 20.8 μg/ml and E-22: 86 μg/ml). Cell death is presented as
mean +/- SD, (n = 4). � indicates a statistically significant difference (p<0.05) compared to the
relevant control.
(TIF)
S1 Dataset. Dataset providing all raw values used to create figures in this manuscript.
Datasets are labelled according to the extracts tested, the type of data (i.e. in vitro or in vivo),
time-point used and which figure the data relates to.
(XLSX)
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